• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在抗原特异性刺激后,工程化 T 细胞中逆转录病毒引入的与内源性 TCR 快速重新表达。

Rapid re-expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen-specific stimulation.

机构信息

Department of Hematology, Leiden University Medical Center, The Netherlands.

出版信息

J Immunother. 2011 Mar;34(2):165-74. doi: 10.1097/CJI.0b013e318206a10c.

DOI:10.1097/CJI.0b013e318206a10c
PMID:21304404
Abstract

To broaden the applicability of cellular immunotherapy, adoptive transfer of T-cell receptor (TCR) transferred T cells may be an attractive strategy. Using this approach, high numbers of defined antigen-specific T cells can be engineered. As the introduced TCR has to compete for cell surface expression with the endogenous TCR, the introduced TCR chains are under control of a strong viral promotor, which, in contrast to the endogenous promotor, is constitutively active. We examined whether this difference in regulation would result in differences in TCR internalization and re-expression of the introduced and endogenous TCR on dual TCR engineered T cells and the antigen-responsiveness of both the TCRs. We showed comparable TCR downregulation of TCRs expressed under regulation of a retroviral promotor or the endogenous promotor. However, the introduced TCRs were rapidly re-expressed on the cell surface after TCR stimulation. Despite rapid re-expression of the introduced TCR, T cells exerted similar antigen-sensitivity compared with control T cells, showing that cell mechanisms other than TCR cell surface expression are involved in antigen-sensitivity directly after antigen-specific stimulation. These results showed that TCR transduced T cells are functionally not different from nontransduced T cells and can potentially be used as an effective treatment strategy.

摘要

为了拓宽细胞免疫治疗的应用范围,过继转移 T 细胞受体(TCR)转导的 T 细胞可能是一种有吸引力的策略。使用这种方法,可以设计出大量的定义明确的抗原特异性 T 细胞。由于引入的 TCR 必须与内源性 TCR 竞争细胞表面表达,因此引入的 TCR 链受强病毒启动子的控制,与内源性启动子相反,该启动子是组成性激活的。我们研究了这种调节上的差异是否会导致双 TCR 工程化 T 细胞上引入的和内源性 TCR 的 TCR 内化和再表达以及两种 TCR 的抗原反应性的差异。我们表明,在逆转录病毒启动子或内源性启动子调节下表达的 TCR 的 TCR 下调具有可比性。然而,在 TCR 刺激后,引入的 TCR 迅速在细胞表面重新表达。尽管引入的 TCR 迅速重新表达,但与对照 T 细胞相比,T 细胞表现出相似的抗原敏感性,表明在抗原特异性刺激后,涉及 TCR 细胞表面表达的其他细胞机制参与了抗原敏感性。这些结果表明,转导 TCR 的 T 细胞在功能上与未转导的 T 细胞没有区别,并且可以作为一种有效的治疗策略。

相似文献

1
Rapid re-expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen-specific stimulation.在抗原特异性刺激后,工程化 T 细胞中逆转录病毒引入的与内源性 TCR 快速重新表达。
J Immunother. 2011 Mar;34(2):165-74. doi: 10.1097/CJI.0b013e318206a10c.
2
Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.通过内源性TCR的特异性沉默提高转导的肿瘤特异性TCR在人淋巴细胞中的表达和反应性。
Cancer Res. 2009 Dec 1;69(23):9003-11. doi: 10.1158/0008-5472.CAN-09-1450. Epub 2009 Nov 10.
3
Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.αβ T细胞受体工程改造的γδ T细胞介导有效的抗白血病反应性。
Cancer Res. 2006 Mar 15;66(6):3331-7. doi: 10.1158/0008-5472.CAN-05-4190.
4
Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.用于简化生成编码T细胞受体的逆转录病毒载体颗粒的悬浮包装细胞系。
Gene Ther. 2007 Apr;14(7):595-603. doi: 10.1038/sj.gt.3302906. Epub 2007 Jan 18.
5
Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice.使用T细胞受体逆转录基因小鼠对体内T细胞选择进行快速分析。
Nat Methods. 2006 Mar;3(3):191-7. doi: 10.1038/nmeth858.
6
Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes.通过使用嗜性和嗜亲性包膜进行假型化,可提高原代小鼠T细胞中人TCR的基因转移效率。
J Gene Med. 2007 Jul;9(7):561-70. doi: 10.1002/jgm.1047.
7
Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function.转基因TCR表达:单链与全长受体构建体对T细胞功能的比较
Cancer Gene Ther. 2004 Jul;11(7):487-96. doi: 10.1038/sj.cgt.7700703.
8
T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.TCR基因转移后T细胞重新靶向EBV抗原:含CD28的受体介导增强的抗原特异性IFNγ产生。
Int Immunol. 2006 Apr;18(4):591-601. doi: 10.1093/intimm/dxh401. Epub 2006 Feb 28.
9
Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.通过过继性T细胞受体转移重建回忆抗原特异性T细胞中人类白细胞抗原II类限制性次要组织相容性抗原特异性:对过继性免疫治疗的意义
Clin Cancer Res. 2007 Jul 1;13(13):4009-15. doi: 10.1158/1078-0432.CCR-07-0286.
10
Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.用于宫颈癌免疫治疗的人乳头瘤病毒16型E7特异性T细胞受体的保存与重定向
Clin Immunol. 2005 Feb;114(2):119-29. doi: 10.1016/j.clim.2004.11.005.

引用本文的文献

1
Evolution by innovation as a driving force to improve TCR-T therapies.通过创新实现进化作为改善TCR-T疗法的驱动力。
Front Oncol. 2023 Sep 21;13:1216829. doi: 10.3389/fonc.2023.1216829. eCollection 2023.
2
Genome-wide off-target analyses of CRISPR/Cas9-mediated T-cell receptor engineering in primary human T cells.原发性人类T细胞中CRISPR/Cas9介导的T细胞受体工程的全基因组脱靶分析。
Clin Transl Immunology. 2022 Jan 23;11(1):e1372. doi: 10.1002/cti2.1372. eCollection 2022.
3
Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections.
保护性 T 细胞受体鉴定用于难治性病毒感染中的原位重编程免疫。
Mol Ther. 2022 Jan 5;30(1):198-208. doi: 10.1016/j.ymthe.2021.05.021. Epub 2021 May 29.
4
Orthotopic T-Cell Receptor Replacement-An "Enabler" for TCR-Based Therapies.正交 T 细胞受体替换 - TCR 为基础疗法的“推动者”。
Cells. 2020 Jun 1;9(6):1367. doi: 10.3390/cells9061367.
5
Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic.同时删除内源性 TCRαβ 用于 TCR 基因治疗可产生改良且安全的细胞治疗方法。
Mol Ther. 2020 Jan 8;28(1):64-74. doi: 10.1016/j.ymthe.2019.10.001. Epub 2019 Oct 4.
6
How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer.今天您希望您的 T 细胞具备何种(特定)功能?通过 TCR 基因转移生成 T 细胞治疗功能。
Front Immunol. 2012 Jul 6;3:186. doi: 10.3389/fimmu.2012.00186. eCollection 2012.